- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05084391
Phase I/II Randomized Study of Stereotactic Ablative Radiotherapy (SABR) Versus Standard of Care for Refractory Structural Cardiac Arrhythmias (SABR-HEART)
Phase I: For the Phase I portion, there will be up to 15 patients treated with SABR and followed for 6 months post-treatment to ensure no significant acute grade 3 or 4 toxicity from SABR treatment. Efficacy as defined below will also be assessed. Following this Phase I lead-in, results will be presented to the FDA for review. Only upon favorable analysis by the FDA committee, and with written explicit permission, will the Phase II randomized portion ensue. This is to act as a safety and efficacy safeguard and has is addressed more thoroughly in the Statistical Analysis Plan of this protocol.
Phase II: A 1:1 randomized Phase II portion with 25 patients in each arm assigned to SABR or current practice (standard of care; Figure 3). Standard of care is defined as nationally recognized appropriate next treatment strategies for medical and catheter-ablation refractory structural cardiac VT that is assessed and judged appropriate for the patient by his/her treating cardiologist. This includes repeat catheter ablation (intravascular and/or epicardial catheter ablation), placement of left-ventricular assist device (LVAD), heart transplant, or further medical management (e.g. antiarrhythmic drug modulation/continuation). Randomization will be performed through the Clinical Trial Conduct (CTC) website.
Study Overview
Status
Intervention / Treatment
Detailed Description
Primary Objectives Phase I:
-Assess acute toxicity and efficacy with SABR in treating refractory structural cardiac ventricular tachyarrhythmias (VT). Ensure safety and treatment efficacy.
Primary Objectives Phase II:
- Investigate overall toxicity with SABR compared to next best management practices (standard of care) in treating refractory structural cardiac ventricular tachyarrhythmias (VT).
- Investigate VT episode reduction with SABR compared to standard of care to evaluate effectiveness and potential superiority of SABR to current day options.
Primary Objectives Phase I:
1. Assess acute toxicity and efficacy with SABR in treating refractory structural cardiac ventricular tachyarrhythmias (VT). Ensure safety and treatment efficacy.
Primary Objectives Phase II:
- Investigate overall toxicity with SABR compared to next best management practices (standard of care) in treating refractory structural cardiac ventricular tachyarrhythmias (VT).
- Investigate VT episode reduction with SABR compared to standard of care to evaluate effectiveness and potential superiority of SABR to current day options.
Secondary Objectives
The following endpoints will be analyzed retrospectively based on prospectively collected (event-free survival endpoints) and at the specified time points (e.g. QOL questionnaire). Participation in QOL assessment and bio specimen collection for secondary endpoints is completely voluntary and not mandated by the trial.
- 6-month and 1-year overall survival (OS) of SABR compared to standard of care.
- Quality of life (QOL) with SABR compared to standard of care (baseline and at 6 months after randomization).
- Hospitalization-free survival with SABR compared to standard of care (evaluated at 1-year).
- Cost-effectiveness analysis with SABR compared to standard of care (evaluated at 1-year).
- Freedom-from Antiarrhythmic medications with SABR compared to standard of care (evaluated at 1-year).
- Freedom-from Electrical Storm with SABR compared to standard of care (evaluated at 1-year).
- Treatment-free Survival with SABR compared to standard of care (evaluated at 1-year).
- Event-free Survival with SABR compared to standard of care (evaluated at 1-year).
- Long term (>1year) toxicity with SABR compared to standard of care (evaluated at 1-year).
- Ejection fraction improvement with SABR compared to standard of care (evaluated at 1-year).
- Transplant/LVAD-free survival with SABR compared to standard of care (evaluated at 1-year).
- Number, type, and treatment success and cycle length of ICD-treated VTs with SABR compared to standard of care (evaluated at 1-year).
- Parameters obtained from cardiac imaging, and/or serum markers will be associated with frequency of survival, response to treatment, and toxicity at regular time intervals using cardiac ECHO, MRI, CT imaging, ICD interrogation, and/or serum/blood work studies for prognostic/predictive biomarker and radiomic identification.
Study Type
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Joe Chang, MD
- Phone Number: (713) 563-2337
- Email: jychang@mdanderson.org
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
Contact:
- Joe Change, MD
- Phone Number: 713-563-2337
- Email: jychang@mdanderson.org
-
Principal Investigator:
- Joe Chang, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ECOG 0-2
- Age 18 years or older
- Diagnosis of recurrent sustained monomorphic VT (MMVT) in the setting of structural heart disease.
- ICD placement and at least two (2) episodes of recurrencerecurrent sustained MMVT that are terminated by anti-tachycardia pacing (ATP) or ICD shocks confirmed by device interrogation in the preceding 3 months, since the last VT ablation procedure in subjected who have failed catheter ablation.
- Failed at least 1 anti-arrhythmic medication (not including beta-blockers) as evidenced by persistent VT (including amiodarone and/or sotalol)
- At least 1 attempted catheter ablation procedure with voltage and/or activation 3D mapping. For patients with ischemic cardiomyopathy this would include failure of at least one endocardial ablation performed at an experienced center. For patients with non-ischemic cardiomyopathy, both endocardial and epicardial ablation should have been attempted unless epicardial ablation/mapping is not feasible (e.g. patient tolerance, deemed futile by EP, prior cardiac surgery).
- Patients are eligible regardless of past or present oncologic history (however, please refer to exclusion criterion #1 below, regarding life-expectancy of at least 12 months in the absence of VT)
Exclusion Criteria:
- Unlikely to live at least 12 months in the absence of VT, as assessed by physicians
- Heart failure dependent on ionotropes
- Left ventricular assist device
- Polymorphic VT
- Ventricular fibrillation
- 5 or more VT morphologies during stimulation testing suggestive of more than one arrhythmogenic substrate
- Prior radiation treatment to the chest for any reason
- Last invasive catheter ablation attempt <2 weeks
- Lack of ICD data in preceding 3 months
- Unable/unwilling to provide informed consent
- Idiopathic VT
- Women who are pregnant
- Heart transplant
- Active ischemia or other reversible causes of VT
- Active non-cardiovascular illness or systemic infection
- Cardiogenic shock
- Presence of incessant VT that is hemodynamically unstable
- Acute heart failure exacerbation
- Revascularization in the past 30 days
- Left ventricular ejection fraction <15%
- Scar tissue exceeding 80cc in volume planning treatment volume (PTV) ≥300cc.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase I:
Phase I there will be up to 15 patients treated with SABR and followed for 6 months post-treatment to ensure no significant acute grade 3 or 4 toxicity from SABR treatment.
|
is safe for treating heart arrhythmias (irregular heartbeat
Standard of care
|
Experimental: Phase II
Phase II portion with 25 patients in each arm assigned to SABR or current practice (standard of care)
|
is safe for treating heart arrhythmias (irregular heartbeat
Standard of care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The overall toxicity as assessed using CTCAE v4.0 will be used with SABR compared to next best management practices (standard of care) in treating refractory structural cardiac ventricular tachyarrhythmias (VT).
Time Frame: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Joe Chang, MD, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019-0538
- NCI-2021-10672 (Other Identifier: Clinical Trials Reporting Program)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiac Arrhythmia
-
Medical University of LodzNot yet recruitingCardiac Arrhythmia | Supraventricular ArrhythmiaPoland
-
Myant Medical Corp.Partners in Advanced Cardiac EvaluationCompleted
-
New York Institute of TechnologyCompleted
-
Kansas City Heart Rhythm InstituteBiosense Webster, Inc.TerminatedArrhythmia, CardiacUnited States
-
Children's National Research InstituteNational Institutes of Health (NIH)CompletedVentricular Tachycardia | Cardiac ArrhythmiaUnited States
-
SanofiCompletedVentricular Arrhythmia | Arrhythmia ProphylaxisNetherlands, Spain, Belgium, Japan, Finland, Chile, Australia, United States, Argentina, Canada, Czech Republic, Denmark, France, Germany, Hungary, Israel, Italy, Mexico, Norway, Poland, Portugal, Russian Federation, Slovakia, South Africa and more
-
Ruiqin xieCompletedSlow Arrhythmia; Left Bundle Branch Pacing; Cardiac FunctionChina
-
Adana City Training and Research HospitalCompleted
-
University of California, San DiegoCompletedAtrioventricular Block | Cardiac Arrhythmia | Sick Sinus Syndrome | Symptomatic BradycardiaUnited States
-
Huawei Device Co., LtdRecruiting
Clinical Trials on stereotactic ablative radiotherapy (SABR)
-
Stanford UniversityVarian, a Siemens Healthineers CompanyActive, not recruitingEmphysemaUnited States
-
University Medical Center GroningenCompleted
-
University of Texas Southwestern Medical CenterActive, not recruitingProstate CancerUnited States
-
Cancer Research AntwerpCompleted
-
Lawson Health Research InstituteLondon Health Sciences FoundationNot yet recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenocarcinoma
-
Mayo ClinicCompleted
-
European Institute of OncologyAssociazione Italiana per la Ricerca sul CancroRecruiting
-
University of Texas Southwestern Medical CenterWithdrawnTachycardia, VentricularUnited States
-
Fudan UniversityRecruiting
-
Trans Tasman Radiation Oncology GroupActive, not recruitingRenal Cell CarcinomaAustralia